Prelude Therapeutics Incorporated (PRLD)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Prelude Therapeutics Incorporated Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 10.12M | $305.1M | $44.24M | -$260.86M | -85.5% |
 Point72 Asset Management LP Point72 Asset Management LP | 16,329 | $47,354.04 | $71,398.55 | $24,044.51 | 50.78% |
| DP Drew Phillips Fortitude Family Office LLC | 230 | $787 | $986.58 | $199.58 | 25.36% |
Prelude Therapeutics Incorporated (PRLD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Prelude Therapeutics Incorporated ever had a stock split?
Prelude Therapeutics Incorporated Profile
| Biotechnology Industry | Healthcare Sector | Krishna Vaddi CEO | NASDAQ (NGS) Exchange | 74065P101 CUSIP |
| US Country | 79 Employees | - Last Dividend | - Last Split | 25 Sep 2020 IPO Date |
Overview
Prelude Therapeutics Incorporated is a clinical-stage biopharmaceutical company engaged in the quest to discover and develop novel precision cancer medicines aimed at addressing the needs of underserved patients. With a strategic focus on developing innovative therapeutic agents for various forms of cancer, the company pursues research and development with a patient-centric approach. Prelude Therapeutics, established in 2016 and headquartered in Wilmington, Delaware, positions itself at the forefront of cancer treatment by targeting specific malignant conditions through a detailed understanding of cancer biology and patient genetics.
Products and Services
- PRT1419
Designed as a myeloid cell leukemia-1 (MCL-1) inhibitor, PRT1419 is currently in Phase 1 clinical trials. This investigational drug targets selected relapsed/refractory myeloid or B-cell malignancies, aiming to offer a new therapeutic approach for patients with these challenging forms of cancer.
- PRT2527
A cyclin-dependent kinase (CDK) in development, PRT2527, is undergoing Phase 1 clinical trials to evaluate its efficacy in treating advanced solid tumors. Through inhibiting specific CDKs, PRT2527 seeks to impair the proliferation of cancer cells, offering a potential pathway for treating various solid malignancies.
- PRT3645
PRT3645 is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor being assessed in Phase 1 clinical trials for its utility in the treatment of advanced and metastatic solid tumors. By targeting CDK4/6, PRT3645 aims to hinder cancer cell growth and proliferation, representing a novel approach to tackling aggressive and advanced forms of cancer.
- PRT3879
Entering Phase 2/3 clinical trials, PRT3879 is a SMARCA2 selective protein degrader being explored for the treatment of advanced and metastatic solid tumors that demonstrate loss of SMARCA4 due to truncating mutation and/or deletion. This innovative therapy focuses on a specific genetic aberration, offering hope for patients with tumors that are difficult to treat with traditional therapies.
- CDK9 Program
The company's CDK9 program revolves around the regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. By targeting CDK9, Prelude aims to disrupt these critical pathways, thereby inhibiting cancer cell growth and survival. This research-focus underscores the company's commitment to unravelling complex cancer biology for the development of more effective treatments.
